Multiple SclerosisDBLNCT06068582
Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis
A study testing Strenghtening the brain and Strengthening the mind in people with Multiple Sclerosis, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.
Trial summary
The goal of this randomized controlled trial is to compare the effectiveness of two innovative interventions aimed at preventing cognitive decline and work-related problems to enhanced usual care in improving quality of life in people with multiple sclerosis. Read more about this study
- Who is it for?
- Ages 18 to 67 years
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- Strenghtening the brain and Strengthening the mind
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 270 participants
- Where
- 1 siteNetherlands
- Study dates
- 16 Apr 2023to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 67 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Confirmed MS diagnosis according to the McDonald 2017 criteria
- Age between 18 and 67
- No changes in disease modifying therapy prior to inclusion (i.e., no changes in last 3 months) - this criterion only applies at inclusion to ensure participants are in a stable situation at the start of the study and for follow-up measures, changes in treatment will be registered but will not result in exclusion from the study
- no current relapse or steroid treatment in the six weeks prior to study visits
- presence of mild cognitive deficits (at least one test with a Z-score of -1.0 to -1.99 below norm scores of healthy controls on the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery
- being able to participate in an exercise intervention (i.e., EDSS < 6.0)
- fulfilling safety criteria for MRI (no metal inside body, not pregnant, no claustrophobia)
Who cannot join
- presence of neurological (other than MS) and psychiatric disorders
- a current or history of drug or alcohol abuse
- being unable to speak or read Dutch
- currently on sick leave for a period of 6 weeks or longer
- currently pregnant
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Netherlands1 site, 1 recruiting
- Recruiting
Amsterdam University Medical Centers, location VUmc
Amsterdam
About this study
The goal of this randomized controlled trial is to compare the effectiveness of two innovative interventions aimed at preventing cognitive decline and work-related problems to enhanced usual care in improving quality of life in people with multiple sclerosis. Secondary objectives are:
- to compare the effectiveness of the investigated interventions in improving cognitive, psychological, and work functioning, and in enhancing the brain's functional network
- to examine which factors (i.e., baseline cognitive, psychological, work, and brain MRI-parameters) are predictive of the response to the investigated interventions
- aim to qualitatively reflect on the process and outcome of the investigated interventions considering the perspectives of relevant stakeholders to allow for smooth and successful implementation in clinical practice
Participants will follow the intervention for four months, with follow-up measurements at six months after intervention and 12 months after intervention.
Read the detailed description
Background Up to 65% of the people with multiple sclerosis (PwMS) develop cognitive deficits that severely affect daily life functioning and PwMS' quality of life. Moreover, approximately 65% of all patients end up unemployed within five years after diagnosis. Current treatments mostly focus on symptom management and return to work, which may be too late. It is hypothesized that timely interventions will help prevent or delay cognitive decline and work-related problems in PwMS, thereby improving quality of life.
Objectives
Primary Objective:
To compare the effectiveness of the investigated interventions with enhanced usual care in improving quality of life.
Secondary Objectives:
- To compare the effectiveness of the investigated interventions in improving cognitive, psychological and work functioning, and in enhancing the brain's functional network.
- To examine which factors (i.e. baseline cognitive, psychological, work and brain MRI-parameters) are predictive of the response to the investigated interventions.
- To qualitatively reflect on the process and outcome of the investigated interventions considering the perspectives of relevant stakeholders to allow for smooth and successful implementation in clinical practice.
- To compare the cost-effectiveness of the investigated interventions.
Material and methods A randomized controlled trial with three arms and three follow-up visits over a total time period of 16 months. During these visits researchers will gather information from questionnaires, neuropsychological examination, MRI and blood sampling. All participants (N= 240) have a confirmed MS diagnosis according to the McDonald 2017 criteria, have subclinical cognitive impairment and are aged between 18 and 67. Participants will be randomly assigned to one of the three arms (N=90 in each arm). Interviews will be conducted with 12-15 participants from both interventions, 10-12 sport coaches, 8-12 work coaches and 10-12 supervisors from the workplace.
'Strengthening the brain' (4 month-program) consists of weekly 30 minutes 1-on-1 exercise and lifestyle coaching in combination with two moments per week unsupervised exercises at home and a home-based online computerized cognitive training. 'Strengthening the mind' (4 month-program) consists of biweekly contact with work coaches who are all diagnosed with MS themselves. 'Enhanced usual care' entails an appointment with a researcher in addition to usual care.
Results The primary outcome is change in quality of life as measured with the 36-item Short Form. Several secondary outcomes will be collected: cognitive, psychological, cost-effectiveness, structural- and functional brain, neurological, physiological, and qualitative measures.
- Conditions
- Multiple Sclerosis
- Being tested
- Strenghtening the brain, Strengthening the mind
- Keywords
- Multiple Sclerosis, Cognition, Exercise, Employment, Prevention, Health-related Quality of Life
- Medical subject headings
- Multiple Sclerosis, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Strenghtening the brainBehavioural
Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.
Strengthening the mindBehavioural
Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.
| Study group | Role | What they receive |
|---|---|---|
| Strengthening the brain | Experimental | Participants receive 30 minutes of 1-on-1 fitness training, dietary advice, and mental coaching, in addition to twice 20 minutes fitness at home, and 60 minutes of cognitive training each week for four months. Receives: Behavioral: Strenghtening the brain |
| Strengthening the mind | Experimental | Partiicpants receive biweekly 1-on-1 coaching by a trained work-coach who has MS to identify challenges at work and implement solutions. It is completed when satisfactory solutions have been implemented for all challenges or after four months. Receives: Behavioral: Strengthening the mind |
| Enhanced usual care | No intervention | Participants receiving general information about cognitive impairment in MS and following care as usual for four months. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Life
Quality of life assessed using the 36-item Short Form. Item-scores are summed and transformed into a total score that ranges 0-100. Higher score corresponds with better quality of life.
Measured: Baseline, Month 4, Month 10, and Month 16
Secondary outcomes (35)
Information processing speed
Information processing speed is assessed using the Symbol Digit Modalities Test (SMDT). The total responses made in 90 seconds is administered. Higher amount of correct responses equals better information processing speed.
Measured: Baseline, Month 4, Month 10, and Month 16
Information processing speed
Information processing speed is assessed using the Paced Auditory Serial Addition Test (PASAT). The total correct answers given, out of 60, is administered. Higher amount of correct responses equals better information processing speed.
Measured: Baseline, Month 4, Month 10, and Month 16
Verbal fluency
Verbal fluency is assessed using the Dutch adaptation of the Controlled Oral Word Association Test; Dutch Letter Fluency Test. Total number of correct words will be administered. Higher score corresponds with better verbal fluency.
Measured: Baseline, Month 4, Month 10, and Month 16
Spatial Processing
Spatial Processing is assessed using the Judgement of Line Orientation. Total correct responses, with maximum 30, will be administered. Higher score corresponds with better spatial processing.
Measured: Baseline, Month 4, Month 10, and Month 16
Verbal New Learning and Memory
New Learning and Memory is assessed using the California Verbal Learning Test, second edition (CVLT-II). Direct recall on the CVLT-II will be administered using number of correctly remembered items over learning trials 1-5. Delayed recall on CVLT-II will be administered using number of correctly remembered items 20 minutes after learning trail 5. Maximum scores for direct recall, delayed recall, and recognition are set at 80, 16, and 44, respectively. Higher score equals better verbal learning and memory.
Measured: Baseline, Month 4, Month 10, and Month 16
Visual New Learning and Memory
New Learning and Memory is assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). Direct recall on BVMT-R will be administered using number of correctly remembered items over learning trials 1-3. Delayed recall on BVMT-R will be administered using number of correctly remembered items 25 minutes after learning trail 3. Maximum scores for direct recall, delayed recall, and recognition are set at 36, 12, and 12, respectively. Higher score equals better visual learning and memory.
Measured: Baseline, Month 4, Month 10, and Month 16
Executive Function
Executive Function is assessed using the Delis-Kaplan Executive Function System. Total correct sorts will be administered, with a maximum of 16 sorts. A higher score suggests better executive functioning.
Measured: Baseline, Month 4, Month 10, and Month 16
Self-Reported Cognitive Functioning
Self-Reported Cognitive Functioning is assessed using the Multiple Sclerosis Neuropsychological Screening Questionnaire. Maximum score of 70 can be reached, with a score of 27 or higher indicating presence of neuropsychological problems.
Measured: Baseline, Month 4, Month 10, and Month 16
Work Participation and Productivity
Work Participation and Productivity is assessed using the Work Productivity and Activity Impairment Questionnaire: General Health, which administers the effect of health-problems on ability to work. Scores are calculated as percentages, with higher numbers indicating greater impairment and less productivity.
Measured: Baseline, Month 4, Month 10, and Month 16
Work Difficulties
Work Difficulties are assessed using the Multiple Sclerosis Work Difficulties Questionnaire. The questionnaire consists of 23 items, which can be grouped into three subscales: psychological/cognitive barriers, physical barriers, and external barriers. The maximum score of each subscale is 100, with higher scores indicating higher perceived difficulties. Total score consists of an average of the three subscale scores.
Measured: Baseline, Month 4, Month 10, and Month 16
Capability to carry out Work Activities
Capability to carry out Work Activities is assessed using the Capability Set for Work Questionnaire. This questionnaire evaluates for seven valued work aspects whether, A) it is important to the worker, B) their work offers sufficient opportunities to do it, and C) it can be achieved, on a 5-point Likert scale.
Measured: Baseline, Month 4, Month 10, and Month 16
Quality of Working Life
Quality of Working Life is assessed using the Quality of Working Life Questionnaire for Cancer Survivors. The questionnaire consists of five subscales: meaning of work, perception of the work situation, atmosphere in the work environment, understandings and recognition in the organisation, and problems due to health situation. The overall score and sum scores of the subscales are calculated with a standardised score 0-100. Higher score corresponds with better quality of working life.
Measured: Baseline, Month 4, Month 10, and Month 16
Grey Matter Volume of the Brain
Grey Matter Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.
Measured: Baseline, Month 4, and Month 16
White Matter Volume of the Brain
White Matter Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.
Measured: Baseline, Month 4, and Month 16
Total Brain Volume
Total Brain Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.
Measured: Baseline, Month 4, and Month 16
Volumes of Deep Grey Matter Structures
Volumes of Deep Grey Matter Structures will be determined using FIRST.
Measured: Baseline, Month 4, and Month 16
Cortical Thickness
Cortical Thickness will be determined using Freesurfer.
Measured: Baseline, Month 4, and Month 16
White Matter Integrity
White Matter Integrity will be determined using Diffusion Tensor Imaging
Measured: Baseline, Month 4, and Month 16
Functional Connectivity
Functional Connectivity will be determined using Resting-State fMRI
Measured: Baseline, Month 4, and Month 16
Regional Functional Activation
Regional Functional Activation will be determined using Task-Based fMRI
Measured: Baseline, Month 4, and Month 16
Fatigue
Fatigue will be assessed using the Checklist Individual Strength. The questionnaire consists of 20 items, scored on a 7-point Likert scale. Fatigue is a subscale of the questionnaire, and is scored by adding the scores of the items, where a higher score corresponds with more fatigue.
Measured: Baseline, Month 4, Month 10, and Month 16
Mood and Anxiety
Mood and Anxiety will be assessed using the Hospital Anxiety and Depression Scale. The questionnaire consists of 14 items on a 4-point Likert scale. The range of scores is 0-21 where a higher score equals more complaints of anxiety and depression.
Measured: Baseline, Month 4, Month 10, and Month 16
Resilience
Resilience will be assessed using the Connor Davidson Resilience Scale. Total score ranges 0-100, with higher scores reflecting greater resilience.
Measured: Baseline, Month 4, Month 10, and Month 16
Perceived Level of Stress
Perceived Level of Stress will be assessed using the Perceived Stress Scale. Total score ranges 0-40, with higher scores indicating higher perceived stress.
Measured: Baseline, Month 4, Month 10, and Month 16
Social Mindfulness
Social Mindfulness will be assessed using the SoMi paradigm by van Doesum et al. (2013). Choices that are made are scores as mindful (1) or unmindful (0). Final score will be computed by averaging the scores over all decisions, resulting in a number between 0 (unmindful) and 1 (mindful).
Measured: Baseline, Month 4, Month 10, and Month 16
Social Participation
Social Participation will be assessed using the PROMIS 'Ability to Participate in Social Roles and Activities' item bank. The questionnaire consists of eight items that can be scored on a 5-point Likert scale. Higher scores indicate better ability to participate in social roles and activities.
Measured: Baseline, Month 4, Month 10, and Month 16
MS-related disability
MS-related disability will be assessed using the Expanded Disability Status Scale. This scale ranges from 0.0 to 10.0, where a higher score indicates worse disability.
Measured: Baseline, Month 4, Month 10, and Month 16
Balance
Balance will be assessed using the Mini-BESTest. The test contains 14 items where a total score of 28 points can be achieved, where a score <19 induces an increased risk of falling.
Measured: Baseline, Month 4, and Month 16
Walking Speed
Walking Speed will be assessed using the Timed 25-Foot Walk.
Measured: Baseline, Month 4, and Month 16
Endurance
Endurance will be assessed using the Shuttle Walk Test according to the protocol of Singh et al. (1992).
Measured: Baseline, Month 4, and Month 16
Grip Strength
Grip Strength will be assessed using a JAMAR hand-held dynamometer.
Measured: Baseline, Month 4, and Month 16
Upper Limb Dexterity
Upper Limb Dexterity will be assessed using the 9-Hole Peg Test and the Purdue Pegboard Test.
Measured: Baseline, Month 4, and Month 16
Lost Productivity Costs
Lost Productivity Costs will be assessed using the iMTA Productivity Cost Questionnaire. The questionnaire consists of three modules measuring absenteeism, presenteeism, and productivity loss from unpaid work.
Measured: Baseline, Month 4, Month 10, and Month 16
Societal Costs including Healthcare, Patient, and family
Societal Costs will be assessed using the iMTA Medical Consumption Questionnaire.
Measured: Baseline, Month 4, Month 10, and Month 16
Quality Adjusted Life Years
Quality Adjusted Life Years will be assessed using the EuroQol five-dimensional Questionnaire. The questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Higher scores indicate more problems considering the dimensions.
Measured: Baseline, Month 4, Month 10, and Month 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2023
- Study start16 Apr 2023
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by Amsterdam UMC, location VUmcThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 270 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Amsterdam UMC, location VUmc
- Sponsor type
- University, hospital or other
- Collaborators
- Universiteit Leiden, Personal Fitness Nederland, MS Vereniging Nederland, Merck B.V., Netherlands, Genzyme, a Sanofi Company, MS Sherpa
- Responsible party
- Principal investigator, Hanneke Hulst, Universiteit Leiden
- Investigators
- Hanneke E Hulst, Principal investigator, Leiden University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06068582
- Sponsor's protocol ID
- NL82007.018.23
- Other IDs
- NWA.1292.19.064
- Acronym
- DBL
- Status last verified
- Mar 2025
- First submitted
- 25 Aug 2023
- Last updated
- 3 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data relating to the main outcomes will be shared in online repository. Coded data will be published in an online scientific archive for the purpose of future research, in line with Open Science practices, and for the verification of findings. These data would not be traceable as they are not linked in any way to personal data. MRI data will be stored in OSF and other platforms that may accommodate the large capacity of the data set.
Publications
Aarts J, Saddal SRD, Bosmans JE, de Groot V, de Jong BA, Klein M, Ruitenberg MFL, Schaafsma FG, Schippers ECF, Schoonheim MM, Uitdehaag BMJ, van der Veen S, Waskowiak PT, Widdershoven GAM, van der Hiele K, Hulst HE; Don't be late! consortium. Don't be late! Postponing cognitive decline and preventing early unemployment in people with multiple sclerosis: a study protocol. BMC Neurol. 2024 Jan 15;24(1):28. doi: 10.1186/s12883-023-03513-y.
PubMed 38225561
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT06068582
- Acronym / sponsor ID
- DBL / NL82007.018.23
- Conditions
- Multiple Sclerosis
- Keywords
- Multiple Sclerosis, Cognition, Exercise, Employment, Prevention, Health-related Quality of Life
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 270 participants (estimated)
- Lead sponsor
- Amsterdam UMC, location VUmcUniversity, hospital or other
- Collaborators
- Universiteit Leiden, Personal Fitness Nederland, MS Vereniging Nederland, Merck B.V., Netherlands, Genzyme, a Sanofi Company, MS Sherpa
- Study start
- 16 Apr 2023 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 5 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this randomized controlled trial is to compare the effectiveness of two innovative interventions aimed at preventing cognitive decline and work-related problems to enhanced usual care in improving quality of life in people with multiple sclerosis. Secondary objectives are:
- to compare the effectiveness of the investigated interventions in improving cognitive, psychological, and work functioning, and in enhancing the brain's functional network
- to examine which factors (i.e., baseline cognitive, psychological, work, and brain MRI-parameters) are predictive of the response to the investigated interventions
- aim to qualitatively reflect on the process and outcome of the investigated interventions considering the perspectives of relevant stakeholders to allow for smooth and successful implementation in clinical practice
Participants will follow the intervention for four months, with follow-up measurements at six months after intervention and 12 months after intervention.
Detailed description
Background Up to 65% of the people with multiple sclerosis (PwMS) develop cognitive deficits that severely affect daily life functioning and PwMS' quality of life. Moreover, approximately 65% of all patients end up unemployed within five years after diagnosis. Current treatments mostly focus on symptom management and return to work, which may be too late. It is hypothesized that timely interventions will help prevent or delay cognitive decline and work-related problems in PwMS, thereby improving quality of life.
Objectives
Primary Objective:
To compare the effectiveness of the investigated interventions with enhanced usual care in improving quality of life.
Secondary Objectives:
- To compare the effectiveness of the investigated interventions in improving cognitive, psychological and work functioning, and in enhancing the brain's functional network.
- To examine which factors (i.e. baseline cognitive, psychological, work and brain MRI-parameters) are predictive of the response to the investigated interventions.
- To qualitatively reflect on the process and outcome of the investigated interventions considering the perspectives of relevant stakeholders to allow for smooth and successful implementation in clinical practice.
- To compare the cost-effectiveness of the investigated interventions.
Material and methods A randomized controlled trial with three arms and three follow-up visits over a total time period of 16 months. During these visits researchers will gather information from questionnaires, neuropsychological examination, MRI and blood sampling. All participants (N= 240) have a confirmed MS diagnosis according to the McDonald 2017 criteria, have subclinical cognitive impairment and are aged between 18 and 67. Participants will be randomly assigned to one of the three arms (N=90 in each arm). Interviews will be conducted with 12-15 participants from both interventions, 10-12 sport coaches, 8-12 work coaches and 10-12 supervisors from the workplace.
'Strengthening the brain' (4 month-program) consists of weekly 30 minutes 1-on-1 exercise and lifestyle coaching in combination with two moments per week unsupervised exercises at home and a home-based online computerized cognitive training. 'Strengthening the mind' (4 month-program) consists of biweekly contact with work coaches who are all diagnosed with MS themselves. 'Enhanced usual care' entails an appointment with a researcher in addition to usual care.
Results The primary outcome is change in quality of life as measured with the 36-item Short Form. Several secondary outcomes will be collected: cognitive, psychological, cost-effectiveness, structural- and functional brain, neurological, physiological, and qualitative measures.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Strengthening the brain | Experimental | Behavioral: Strenghtening the brainParticipants receive 30 minutes of 1-on-1 fitness training, dietary advice, and mental coaching, in addition to twice 20 minutes fitness at home, and 60 minutes of cognitive training each week for four months. |
| Strengthening the mind | Experimental | Behavioral: Strengthening the mindPartiicpants receive biweekly 1-on-1 coaching by a trained work-coach who has MS to identify challenges at work and implement solutions. It is completed when satisfactory solutions have been implemented for all challenges or after four months. |
| Enhanced usual care | No intervention | –Participants receiving general information about cognitive impairment in MS and following care as usual for four months. |
Who may qualify
- Ages
- 18 to 67 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Confirmed MS diagnosis according to the McDonald 2017 criteria
- Age between 18 and 67
- No changes in disease modifying therapy prior to inclusion (i.e., no changes in last 3 months) - this criterion only applies at inclusion to ensure participants are in a stable situation at the start of the study and for follow-up measures, changes in treatment will be registered but will not result in exclusion from the study
- no current relapse or steroid treatment in the six weeks prior to study visits
- presence of mild cognitive deficits (at least one test with a Z-score of -1.0 to -1.99 below norm scores of healthy controls on the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery
Key exclusion criteria (5 listed)
- presence of neurological (other than MS) and psychiatric disorders
- a current or history of drug or alcohol abuse
- being unable to speak or read Dutch
- currently on sick leave for a period of 6 weeks or longer
- currently pregnant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Strenghtening the brainLifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week. | Behavioural | Strengthening the brain |
| Strengthening the mindWork-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions. | Behavioural | Strengthening the mind |
Primary outcome
Quality of Life
Time frame: Baseline, Month 4, Month 10, and Month 16
Quality of life assessed using the 36-item Short Form. Item-scores are summed and transformed into a total score that ranges 0-100. Higher score corresponds with better quality of life.
35 secondary outcomes
Information processing speed
Time frame: Baseline, Month 4, Month 10, and Month 16
Information processing speed
Time frame: Baseline, Month 4, Month 10, and Month 16
Verbal fluency
Time frame: Baseline, Month 4, Month 10, and Month 16
Spatial Processing
Time frame: Baseline, Month 4, Month 10, and Month 16
Verbal New Learning and Memory
Time frame: Baseline, Month 4, Month 10, and Month 16
Visual New Learning and Memory
Time frame: Baseline, Month 4, Month 10, and Month 16
Executive Function
Time frame: Baseline, Month 4, Month 10, and Month 16
Self-Reported Cognitive Functioning
Time frame: Baseline, Month 4, Month 10, and Month 16
Work Participation and Productivity
Time frame: Baseline, Month 4, Month 10, and Month 16
Work Difficulties
Time frame: Baseline, Month 4, Month 10, and Month 16
Capability to carry out Work Activities
Time frame: Baseline, Month 4, Month 10, and Month 16
Quality of Working Life
Time frame: Baseline, Month 4, Month 10, and Month 16
Grey Matter Volume of the Brain
Time frame: Baseline, Month 4, and Month 16
White Matter Volume of the Brain
Time frame: Baseline, Month 4, and Month 16
Total Brain Volume
Time frame: Baseline, Month 4, and Month 16
Volumes of Deep Grey Matter Structures
Time frame: Baseline, Month 4, and Month 16
Cortical Thickness
Time frame: Baseline, Month 4, and Month 16
White Matter Integrity
Time frame: Baseline, Month 4, and Month 16
Functional Connectivity
Time frame: Baseline, Month 4, and Month 16
Regional Functional Activation
Time frame: Baseline, Month 4, and Month 16
Fatigue
Time frame: Baseline, Month 4, Month 10, and Month 16
Mood and Anxiety
Time frame: Baseline, Month 4, Month 10, and Month 16
Resilience
Time frame: Baseline, Month 4, Month 10, and Month 16
Perceived Level of Stress
Time frame: Baseline, Month 4, Month 10, and Month 16
Social Mindfulness
Time frame: Baseline, Month 4, Month 10, and Month 16
Social Participation
Time frame: Baseline, Month 4, Month 10, and Month 16
MS-related disability
Time frame: Baseline, Month 4, Month 10, and Month 16
Balance
Time frame: Baseline, Month 4, and Month 16
Walking Speed
Time frame: Baseline, Month 4, and Month 16
Endurance
Time frame: Baseline, Month 4, and Month 16
Grip Strength
Time frame: Baseline, Month 4, and Month 16
Upper Limb Dexterity
Time frame: Baseline, Month 4, and Month 16
Lost Productivity Costs
Time frame: Baseline, Month 4, Month 10, and Month 16
Societal Costs including Healthcare, Patient, and family
Time frame: Baseline, Month 4, Month 10, and Month 16
Quality Adjusted Life Years
Time frame: Baseline, Month 4, Month 10, and Month 16
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2025.
- Derived from this study: PubMed 38225561Aarts J, Saddal SRD, Bosmans JE, de Groot V, de Jong BA, Klein M, Ruitenberg MFL, Schaafsma FG, Schippers ECF, Schoonheim MM, Uitdehaag BMJ, van der Veen S, Waskowiak PT, Widdershoven GAM, van der Hiele K, Hulst HE; Don't be late! consortium. Don't be late! Postponing cognitive decline and preventing early unemployment in people with multiple sclerosis: a study protocol. BMC Neurol. 2024 Jan 15;24(1):28. doi: 10.1186/s12883-023-03513-y.
- Individual participant dataSharing planned: Yes. Data relating to the main outcomes will be shared in online repository. Coded data will be published in an online scientific archive for the purpose of future research, in line with Open Science practices, and for the verification of findings. These data would not be traceable as they are not linked in any way to personal data. MRI data will be stored in OSF and other platforms that may accommodate the large capacity of the data set.
Related trials for Multiple Sclerosis
Active, not recruiting
Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)
PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Not yet recruitingPhase 1
A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Recruiting
Virtual Reality Versus Mental Practice On Balance And Gait In Patients With Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hanneke E Hulst principal investigator
Leiden University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Strenghtening the brain and Strengthening the mind in people with Multiple Sclerosis, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jip Aarts (+31 71 5275081, j.aarts@fsw.leidenuniv.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of Life (time frame: Baseline, Month 4, Month 10, and Month 16). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06068582, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2025.